15.40
+2.33%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mentice
Its shares trade on Nasdaq Stockholm under the ticker MNTC.ST. It has been listed since 18 June 2019. In the fiscal year to 31 December 2025, it reported revenue of SEK 279.1m and a net loss of SEK 32.3m. At that date it held total assets of SEK 312.0m and shareholders' equity of SEK 138.4m.
Mentice AB provides software and hardware simulation solutions for endovascular therapies. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2019-06-18. The company provides software and hardware simulation solutions and related services for endovascular therapies. The Company’s solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Company’s solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The firm also covers neurovascular, cardiovascular and peripheral interventions, among others. The company is active globally.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 18 Jun 2019
- Employees
- 112
- Website
- mentice.com ↗
Leadership
Pay as last reported
- Dr. Magnus NilssonIndependent Chairman of the BoardSEK 470,000
- Mr. Frans VenkerPresident, Group Chief Executive Officer
- Ms. Ulrika VokseppChief Financial Officer
- Mr. Jonatan SjostromChief Operating Officer
- Mr. Matar DakhilExecutive Vice President - Business Development
- Mr. Henrik StormChief Technology Officer
- Mr. Alex HusseinVice President, General Manager - Americas
- Mr. Martin HarrisVice President - Marketing & Sales Enablement, since 2023
- Mr. Edward FaltChief Strategy Officer
- Mr. Lawrence HowellDirector, since 2011SEK 20,000
- Mr. Gosta JohannessonDirectorSEK 210,000
- Mr. David BallardIndependent Director, since 2019SEK 220,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 18
- Social
- 51
- Governance
- 24
- Direct emissions (scope 1)
- 0 t
- Energy emissions (scope 2)
- 190.1 t
- Value chain emissions (scope 3)
- 892.2 t
- Women in the workforce
- 23.66%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mentice AB's endovascular therapy simulation solutions are scientifically validated and used globally.
- The company employs 112 full-time employees with expertise in healthcare simulation technology.
- Mentice AB's solutions cover neurovascular, cardiovascular, and peripheral interventions effectively.
Weaknesses
- Mentice AB's IPO on 18 June 2019 may limit capital for expansion in competitive markets.
- The company's focus on healthcare simulation may restrict diversification into other sectors.
- Mentice AB's headquarters in Goeteborg, Sweden, could limit local market access in key regions.
Opportunities
- Growing demand for endovascular therapy training solutions in the global healthcare sector.
- Expansion into new markets like Asia-Pacific for healthcare simulation services.
- Partnerships with medical device manufacturers to enhance product offerings.
Threats
- Intense competition from established healthcare simulation providers in the global market.
- Regulatory changes in healthcare technology could impact product validation.
- Economic downturns may reduce healthcare spending on simulation training.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.